By Nicholas Civitarese, Research Analyst, LSN
Early stage therapeutics companies have a long road ahead to reach the marketplace, and will require significant investment along their way. The search for development capital is therefore a constant challenge for therapeutics startups.
Life Science Nation is pleased to announce a panel of 5 people with extensive experience in early stage therapeutics for RESI San Francisco on January 12th. Moderated by Dennis Purcell, Founder and Senior Advisor at Aisling Capital, the panel will feature:
- Brent, Ahrens, General Partner, Canaan Partners
- Chris Haskell, Head, US Science Hub, Bayer Pharmaceuticals
- Neil Littman, Business Development Officer, California Institute for Regenerative Medicine
- Shelley Chu, Partner, Abingworth
This panel will give fundraising entrepreneurs a firsthand look at the strategies used by early stage therapeutic investors to assess companies at the earliest, riskiest stage of development, and will help the audience to position their companies as an attractive investment opportunity.
By registering for RESI San Francisco, you’ll be able to listen to the early stage therapeutic panel live in person. January 12th will be our largest conference yet and provides fundraising entrepreneurs with numerous opportunities to expand their network in the life sciences and to learn more about the fundraising process.